Johnson & Johnson Innovation-JJDC logo

Johnson & Johnson Innovation-JJDC

Crunchbase
Pitchbook
Crunchbase

Deals on record

14

Common Fundraising Type

Series B

Alessa Therapeutics logo
Alessa Therapeutics

Drug development

Mission BioCapital logo
Johnson & Johnson logo

Alessa Therapeutics develops localized drug delivery systems for early cancer treatment, focusing on minimizing systemic side effects.

Seed
$15M
12/13/2024
Article
Cala Health logo
Cala Health

Bioelectronic

Vertex Growth Fund logo
TriVentures logo
Reimagined Ventures logo
OSF Ventures logo
Peak6 logo
Nexus NeuroTech Ventures logo
Lux Capital logo
Lightstone logo

Cala Health develops non-invasive, FDA-cleared wearable devices for hand tremor relief, focusing on essential tremor and Parkinson's disease.

Equity
$50M
12/09/2024
Article
Citryll logo
Citryll

Biotech

Forbion logo
Novartis logo
Johnson & Johnson Innovation logo
Seventure Partners logo
Pureos Bioventures logo
Curie Capital logo
BioGeneration Ventures logo
BOM logo

Citryll is a biotech company developing therapies for immune-mediated inflammatory diseases, focusing on a monoclonal antibody targeting Neutrophil Extracellular Traps (NETs).

Series B
$89.8M
12/09/2024
Article
TRexBio logo
TRexBio

Biotechnology

Delos Capital logo
Avego BioScience Capital logo
SV Health Investors logo
Pfizer Ventures logo
Polaris Partners logo
Johnson & Johnson logo
Eli Lilly and Company logo
Agent Capital logo

TRexBio is a biotechnology company developing novel therapies for inflammatory diseases using their Deep Biology platform to focus on immune homeostasis.

Series B
$84M
11/13/2024
Article
Orasis Pharmaceuticals logo
Orasis Pharmaceuticals

Corrective eye drops

Arboretum Ventures logo
Visionary Ventures logo
Sequoia Capital logo
SBI logo
Maverick Ventures logo
Johnson & Johnson Innovation logo
Freepoint Capital Group logo
Catalio Capital Management logo

Orasis Pharmaceuticals develops and commercializes corrective eye drops for treating presbyopia in adults.

Hybrid D
$83M
10/08/2024
Article
SpectraWAVE logo
SpectraWAVE

Medical imaging

SV Health Investors logo
S3 Ventures logo
NovaVenture logo
Johnson & Johnson Innovation - JJDC logo
Heartwork Capital logo
Deerfield Management logo
Lumira Ventures logo

SpectraWAVE, Inc. develops advanced medical imaging systems to improve coronary stenting procedures and enhance clinical decision-making in the treatment of coronary artery disease.

Series B
$50M
09/11/2024
Article
HistoSonics logo
HistoSonics

Medical device

Alpha Wave Ventures logo
Yonjin Venture logo
Venture Investors logo
Wisconsin Investment Board logo
Johnson & Johnson Innovation - JJDC logo
Lumira Ventures logo
HealthQuest Capital logo

HistoSonics is a medical device company that develops non-invasive histotripsy platforms, including the Edison® Histotripsy System, to mechanically destroy and liquefy targeted liver tumors using focused ultrasound.

Series D
$102M
08/15/2024
Article
Aro Biotherapeutics logo
Aro Biotherapeutics

Biotechnology

Cowen Healthcare Investments logo
Johnson & Johnson Innovation logo
Northpond Ventures logo
Healthcap logo
BVF Partners logo

Aro Biotherapeutics is a clinical stage biotech company specializing in the development of tissue-targeted genetic medicines, including a potential treatment for Pompe Disease and new therapies for autoimmune disorders, using their proprietary Centyrin-siRNA platform.

Series B
$41.5M
11/28/2023
Article

On Target Laboratories develops and commercializes FDA-approved imaging agents for cancer surgeries, using near-infrared dye and targeting molecules to aid in detecting and resecting cancer cells.

Series C
$30M
11/16/2023
Article
RefleXion Medical logo
RefleXion Medical

Therapeutic Oncology

Venrock logo
TPG logo
T.Rowe Price Associates logo
Square Point Capital logo
Pictet logo
Pfizer Ventures logo
Johnson & Johnson Innovation logo
Hillenbrand logo

RefleXion Medical develops and commercializes SCINTIX therapy, a novel treatment for all stages of indicated solid tumor cancers, including metastatic disease, delivered via the RefleXion X1 platform.

Equity
$105M
11/15/2023
Article
Osteal Therapeutics logo
Osteal Therapeutics

Biopharmaceutical

Osteal Therapeutics is a clinical-stage biopharmaceutical company that develops novel musculoskeletal therapeutics to treat orthopedic infections, with its lead therapy, VT-X7, currently in Phase 2 development for chronic periprosthetic joint infections.

Series C
$23M
09/21/2023
Article

Arialys Therapeutics is a biotechnology company that develops precision medicines to target pathogenic autoantibodies in the central nervous system, with a focus on treating neuropsychiatric diseases caused by autoimmunity.

Seed
$58M
09/13/2023
Article
ROME Therapeutics logo
ROME Therapeutics

Biotechnology

Section 32 logo
Sanofi Ventures logo
Raycap logo
Mirae Asset Capital logo
Mass General Brigham Ventures logo
Luma Group logo
Johnson & Johnson Innovation-JJDC logo
GV logo

ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.

Series B
$72M
09/12/2023
Article

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.

Series B
$150M
08/23/2023
Article